ERBB2 and breast cancer: In the present study we evaluated the effect of mono-therapies and combination therapy on spontaneous primary mammary tumors from LKB1−/−NIC mice that we previously characterized as hyperactive for mTOR and enhanced metabolic activities promoted by the loss of LKB1 expression and gain of ErbB2 function [9].